Skip to main content
. Author manuscript; available in PMC: 2013 Jun 2.
Published in final edited form as: Gut. 2011 Sep 19;61(5):665–672. doi: 10.1136/gutjnl-2011-300641

Table 6.

Adjusted tertiles of insulin, HOMA-IR, IGF-1 and IGFBPs in BO cases compared with GORD controls, screening colonoscopy controls and matched colonoscopy control subset: multivariate analyses not adjusted for waist-to-hip ratio

Tertiles
1 2 3 p Value (trend)* 2 3 p Value (trend)* 2 3 p Value (trend)*
BO cases vs GORD controls BO cases vs screening colonoscopy controls BO cases vs matched colonoscopy controls
Insulin, OR (95% CI) 1.0 (referent) 1.11 (0.58 to 2.12) 1.15 (0.61 to 2.14) 0.65 0.55 (0.30 to 1.00) 1.64 (1.01 to 2.67) 0.04 0.63 (0.29 to 1.37) 1.87 (0.99 to 3.53) 0.03
HOMA-IR, OR (95% CI) 1.0 (referent) 0.95 (0.49 to 1.84) 1.09 (0.59 to 2.03) 0.76 0.52 (0.28 to 0.95) 1.74 (1.07 to 2.84) 0.02 0.66 (0.31 to 1.43) 2.00 (1.05 to 3.79) 0.02
IGF-1, OR (95% CI) 1.0 (referent) 0.43 (0.22 to 0.83) 0.54 (0.28 to 1.06) 0.44 0.69 (0.37 to 1.30) 1.78 (1.04 to 3.03) 0.01 1.86 (0.77 to 4.44) 5.75 (2.57 to 12.8) <0.001
IGFBP-1, OR (95% CI) 1.0 (referent) 1.07 (0.57 to 2.02) 0.87 (0.46 to 1.67) 0.69 0.26 (0.15 to 0.45) 0.07 (0.03 to 0.16) <0.001 0.41 (0.21 to 0.77) 0.14 (0.05 to 0.33) <0.001
IGFBP-3, OR (95% CI) 1.0 (referent) 0.65 (0.35 to 1.22) 0.30 (0.14 to 0.64) 0.02 0.69 (0.41 to 1.14) 0.30 (0.16 to 0.56) 0.0001 1.11 (0.60 to 2.09) 0.45 (0.21 to 0.95) 0.05
Molar,† OR (95% CI) 1.0 (referent) 1.16 (0.62 to 2.19) 1.11 (0.58 to 2.13) 0.73 0.33 (0.13 to 0.83) 1.91 (1.10 to 3.30) 0.003 2.36 (0.76 to 7.32) 16.81 (5.71 to 49.5) <0.001
*

Adjusted for age, gender and race (Caucasian vs other).

†

Molar represents molar ratio of IGF-1 to IGFBP-3.

BO, Barrett’s oesophagus; GORD, gastro-oesophageal reflux disease; HOMA-IR, homeostatic model for assessment of insulin resistance; IGF-1, insulin growth factor 1; IGFBP-1, IGFBP-3, IGF binding proteins 1 and 3.